Mouse CD20 expression and function

Junji Uchida¹, Youngkyun Lee¹, Minoru Hasegawa¹, Yinghua Liang¹, Alice Bradney¹, Julie A. Oliver¹, Kristina Bowen¹, Douglas A. Steeber¹, Karen M. Haas¹, Jonathan C. Poe¹ and Thomas F. Tedder¹

¹Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA

Keywords: B lymphocyte, immunotherapy, knockout mouse, mAb, signal transduction

Abstract

CD20 plays a role in human B cell proliferation and is an effective target for immunotherapy. In this study, mouse CD20 expression and biochemistry were assessed for the first time using a new panel of CD20-specific mAb, with CD20 function assessed using CD20-deficient (CD20−/−) mice. CD20 expression was B cell restricted and was initiated during late pre-B cell development. The frequency and density of CD20 expression increased during B cell maturation in the bone marrow, with a subpopulation of transitional IgMhi B cells expressing higher CD20 levels than the majority of mature recirculating B cells. Transitional T1 B cells in the spleen also expressed high CD20 levels, providing a useful new marker for this B cell subset. In CD20−/− mice, immature and mature B cell IgM expression was ~20±30% lower relative to B cells from wild-type littermates. In addition, CD19-induced intracellular calcium responses were significantly reduced in CD20−/− B cells, with a less dramatic effect on IgM-induced responses. These results reveal a role for CD20 in transmembrane Ca²⁺ movement in mouse primary B cells that complements previous results obtained using human CD20 cDNA-transfected cell lines. Otherwise, B cell development, tissue localization, signal transduction, proliferation, T cell-dependent antibody responses and affinity maturation were normal in CD20−/− mice. Thus, mouse and human CD20 share similar patterns of expression and function. These studies thereby provide an animal model for studying CD20 function in vivo and the molecular mechanisms that influence anti-CD20 immunotherapy.

Introduction

CD20 is a B lymphocyte-specific cell-surface molecule involved in the regulation of transmembrane Ca²⁺ conductance and cell-cycle progression during human B cell activation (1). CD20 is first expressed by human pre-B cells in the bone marrow, predominantly after Ig heavy chain rearrangement, with expression persisting until plasma cell differentiation (2–4). A limited analysis of CD20 transcripts in mouse cell lines and tissues suggests that mouse CD20 is also B cell specific (5). Both human and mouse CD20 cDNAs encode a membrane-embedded protein with hydrophobic regions of sufficient lengths to pass through the membrane 4 times (5–8). Mouse and human CD20 are well conserved (73%) in amino acid sequence, particularly the transmembrane and long N- and C-terminal cytoplasmic domains (5). The cytoplasmic domains are serine and threonine rich with multiple consensus sequences for phosphorylation. Human CD20 is not glycosylated, but three isoforms (33, 35 and 37,000 Mᵦ) result from the differential phosphorylation of a single protein on different serine and threonine residues (9–11).

CD20 plays a role in the regulation of human B cell activation, proliferation and Ca²⁺ transport (12,13). Antibody ligation of CD20 can generate transmembrane signals that result in enhanced CD20 phosphorylation (10), induction of c-myc and B-myb oncogene expression (14,15), induced serine/threonine and tyrosine phosphorylation of cellular proteins (16), increased CD18, CD58 and MHC class II molecule expression (17,18), and protein tyrosine kinase activation that induces B cell adhesion (19). CD20 ligation promotes transmembrane Ca²⁺ transport (13), but does not usually lead to increased intracellular calcium ([Ca²⁺]ᵢ) levels (13,20,21), except after extensive cross-linking (16). Antibody binding to CD20 inhibits B cell progression from the G₁ phase into the S/G₂ + M stages of the cell cycle following mitogen stimulation, and inhibits mitogen-induced B cell differentiation and antibody secretion (12,20–22). Extensive CD20 cross-linking can also influence apoptosis (23,24). These divergent observations may be explained in part by the finding that CD20 is a component of an oligomeric complex that forms a membrane transporter or Ca²⁺ ion channel that is activated...
during cell-cycle progression (13,25±27). Despite this, B cell development and function in a line of CD20-deficient (CD20±) mice is reported to be normal (28).

The majority of human B cell-lineage malignancies express CD20 (29). Because of this, anti-CD20 mAb have become an effective therapy for non-Hodgkin's lymphoma (30-37). Whether CD20 function or its membrane-embedded structure contributes most to its effectiveness as a therapeutic target remains an open issue since studies assessing in vivo B cell function and therapeutic mechanisms are difficult in humans. To address this, and determine whether and how CD20 regulates normal mouse B cell function and development, we have generated mAb reactive with mouse CD20 and CD20± mice. These reagents have allowed the characterization of CD20 expression in mouse and assessment of its role in mouse B cell function.

Methods
Generation of CD20±/± mice
DNAs encoding the 3’ end of the Cd20 gene were isolated from a 129/Sv strain mouse DNA phage library, mapped and sequenced to identify intron/exon boundaries (Fig. 1A and B) (38). Gene targeting used a pBluescript SK-based vector (p594; David Milstone, Brigham and Women’s Hospital, Boston, MA) containing a PstI (exon 5) through EcoRV (exon 6, ~1.8 kb) DNA fragment downstream of the pMC1-HSV 120 Altered calcium conductance in CD20± mice

Downloaded from https://academic.oup.com/intimm/article-abstract/16/1/119/721734 by guest on 05 March 2018
gene. An ~10 kb KpnI DNA fragment was inserted downstream of the neomycin resistance (Neo') marker (Fig. 1C). The plasmid was linearized using a unique SalI restriction site and used to transfet 129 strain-derived embryonic stem (ES) cells that were selected with G418 as described (39). Six of 115 Neo-resistant ES cell colonies carried the targeted allele (Fig. 1D). Appropriate targeting was further verified by Southern analysis of DNA digested with BamHI (>12-kb fragment reduced to a 6.5-kb band), KpnI (7.2 became 5.5 kb) and SspI (5.6 became 7.0 kb) using the same probe. Cells of one ES cell clone generated 80–100% chimeric male offspring that were crossed with C57BL/6 mice for seven or more generations. Heterozygous offspring were crossed to generate homozygous CD20+/− and wild-type littermates (Fig. 1E). In most cases, results obtained using wild-type littermates of CD20+/− mice and (C57BL/6 × 129)F1 mice were identical, so the results were pooled. Spleen and peritoneal cavity subset analysis was carried out using three to 10 littermates pairs at various ages, so only comparisons between wild-type and CD20+/− mice are valid. Mice were housed in a specific-pathogen-free barrier facility and used at 2–3 months of age. The Animal Care and Use Committee of Duke University approved these studies.

Immunofluorescence analysis

Single-cell leukocyte suspensions were stained on ice using predetermined optimal concentrations of each antibody for 20–60 min as described (40). Cells with the forward and side light scatter properties of lymphocytes were analyzed on FACScan or FACSCalibur flow cytometers (Becton Dickinson, San Jose, CA). Background staining was determined using unreactive control mAb (Caltag, Burlingame, CA) with gates positioned to exclude 98% of the cells. Antibodies used included: CD19 mAb (MB19-1) (9–11), B220 mAb (RA3-6B2; provided by Dr Robt Coffman, DNAX, Palo, Alto, CA; Thy-1.2 (Caltag); antibodies reactive with IgM, I-A, CD5, CD11b, CD23 and CD43 (BD Pharmingen, Franklin Lakes, NJ); and anti-mouse IgG3, IgM and IgD antibodies (Southern Biotechnology Associates, Birmingham, AL).

Hybridomas producing CD20-specific mouse mAb were generated by the fusion of NS-1 myeloma cells with spleen cells from CD20+/− mice immunized with murine CD20-green fluorescent protein (GFP) transfected 300.19 cells (41). The anti-CD20 mAb MB20-1, -2 and -14 were of the IgG1 isotype, MB20-6, -11 and -16 were IgG2a, MB20-7, -8, -10 and -18 were IgG2b, and MB20-3 and -13 were IgG3 mAb. CHO cells and the 300.19 pre-B cell line expressing mouse CD20 fused with GFP were generated by transfecting each cell line with cDNA encoding the fused proteins (5). Transfected cells were isolated by fluorescence-based cell sorting based on GFP expression.

Intracellular Ca2+ measurements

Changes in [Ca2+]i levels were monitored by flow cytometry as described (42) after treating the cells with goat F(ab')2, anti-IgM antibody (5–40 µg/ml; Cappel/ICN, Aurora, OH), anti-mouse CD19 mAb (MB19-1, 40 µg/ml), thepargin (1 µM; Sigma, St Louis, MO) or ionomycin (2.67 µg/ml; Calbiochem, La Jolla, CA). In some cases, EGTA (5 mM final) was added to the cell suspension, followed by the agents described above.

B cell activation assays

Spleen B cells were purified (>93% B220+) by removing T cells with Thy-1.2 antibody-coated magnetic beads (Dynal, Lake Success, NY). For signal transduction studies, B cells were incubated (2 × 105/ml) in RPMI 1640 medium containing 5% FCS at 37°C for 5 min before adding F(ab')2 anti-mouse IgM antibody fragments (40 µg/ml). After adding cold saline containing 400 µM EDTA and 100 µM sodium orthovanadate, the cells were then detergent lysed as described (43,44). For CD20 structural studies, B cells were surface biotinylated with EZ-Link Sulfo-NHS-Biotin (0.5 mg/ml; Pierce, Rockford, IL), then detergent lysed. Cell lysates were precleared with IgG1 mAb (1 µg) and 50 µl of a 50% suspension of Protein G-Sepharose (Amersham Biosciences, Piscataway, NJ), with proteins immunoprecipitated using 2 µg of mAb and Protein G-Sepharose. The beads were washed twice with high- and low-salt RIPA buffers, twice with PBS, boiled in sample buffer.
Altered calcium conductance in CD20−/− mice

Table 1. Frequencies and numbers of B cells in CD20−/− mice

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Phenotype</th>
<th>Percentage of B lymphocytes</th>
<th>B cell numbers (×10^6)</th>
<th>IgM levels in CD20−/− mice (percentage of wild-type)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Wild-type</td>
<td>CD20−/−</td>
<td></td>
</tr>
<tr>
<td>Bone Marrow</td>
<td>IgM+, B220+</td>
<td>28 ± 3</td>
<td>27 ± 3</td>
<td>62 ± 3**</td>
</tr>
<tr>
<td></td>
<td>IgM+, B220lo</td>
<td>14 ± 2</td>
<td>11 ± 1</td>
<td>93 ± 7</td>
</tr>
<tr>
<td></td>
<td>IgM-, B220lo</td>
<td>13 ± 1</td>
<td>17 ± 2</td>
<td></td>
</tr>
<tr>
<td>Blood</td>
<td>IgM+, B220+</td>
<td>63 ± 1</td>
<td>67 ± 2</td>
<td>3.0 ± 0.3 3.7 ± 0.4 69 ± 11*</td>
</tr>
<tr>
<td>Spleen</td>
<td>IgM+, B220+</td>
<td>46 ± 4</td>
<td>50 ± 4</td>
<td>50 ± 8 66 ± 6 78 ± 6**</td>
</tr>
<tr>
<td></td>
<td>IgM+, B220lo</td>
<td>4 ± 2</td>
<td>1 ± 1*</td>
<td>2.0 ± 0.3 0.8 ± 0.3*</td>
</tr>
<tr>
<td></td>
<td>CD21+, HSA+</td>
<td>17 ± 1</td>
<td>22 ± 2*</td>
<td>7.4 ± 0.8 11.2 ± 1.4</td>
</tr>
<tr>
<td></td>
<td>CD21+, HSA−</td>
<td>14 ± 2</td>
<td>9 ± 1*</td>
<td>6.1 ± 1.2 4.5 ± 0.4</td>
</tr>
<tr>
<td></td>
<td>CD1d+, CD21+</td>
<td>5 ± 1</td>
<td>4 ± 1</td>
<td>2.6 ± 0.6 1.8 ± 0.3</td>
</tr>
<tr>
<td>Lymph node</td>
<td>IgM+, B220+</td>
<td>21 ± 4</td>
<td>20 ± 1</td>
<td>1.0 ± 0.2 1.4 ± 0.3 88 ± 10</td>
</tr>
<tr>
<td>Peritoneum</td>
<td>IgM+, B220+</td>
<td>73 ± 3</td>
<td>63 ± 5</td>
<td>1.1 ± 0.2 1.5 ± 0.2 84 ± 6</td>
</tr>
<tr>
<td></td>
<td>CD5+, B220+</td>
<td>45 ± 3</td>
<td>16 ± 5**</td>
<td>0.8 ± 0.1 0.4 ± 0.1**</td>
</tr>
<tr>
<td></td>
<td>CD11b+CD5+, B220+</td>
<td>12 ± 1</td>
<td>12 ± 1</td>
<td>0.3 ± 0.1 0.3 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>CD5−, B220−</td>
<td>28 ± 1</td>
<td>55 ± 3**</td>
<td>0.5 ± 0.1 1.1 ± 0.2*</td>
</tr>
</tbody>
</table>

aValues represent mean (± SEM) numbers or percentages of lymphocytes (based on side and forward light scatter properties) expressing the indicated cell-surface markers from three to 10 wild-type and CD20+/− 2-month-old littermates.
bB cell numbers were calculated based on total numbers of cells harvested from each tissue.
cValues indicate numbers of cells/ml.
dValues for pairs of inguinal lymph nodes.

Sample means were significantly different from wild-type littermates, *P < 0.05; **P < 0.01.

(whether with or without 10% 2-mercaptoethanol), electrophoresed, and transferred to nitrocellulose membranes. Blots of whole-cell lysates were probed with MB20-1 mAb, peroxidase-conjugated 4G10 antibody (Upstate Biotechnology, Lake Placid, NY), with anti-phospho-CD19 (Y513), -phospholipase Cy (Y783), -Syk (Y525/Y526), -BTK (Y223), -Src family kinase antibodies (Cell Signaling Technology, Beverly, MA) or anti-active MAPK antibody (Promega, Madison, WI). The membranes were stripped and reprobed with a rabbit polyclonal anti-SHP-1 antibody (Upstate Biotechnology) or anti-Lyn (Lyn-44), anti-Fyn (Fyn3) and anti-ERK2 (C-14) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA). Biotinylated proteins or antibodies were detected using streptavidin-conjugated horseradish peroxidase (Southern Biotechnology Associates) and an enhanced chemiluminescence kit (Pierce).

For studies of CD20 phosphorylation, primary B cells (10^7/ml) were cultured with lipopolysaccharide (LPS, Escherichia coli serotype 0111:B4, 10 μg/ml; Sigma) for 48 h. Primary B cells and cell lines were then cultured in phosphate-free media for 1 h, cultured in medium containing 200 μCi/ml [32P]orthophosphate (PerkinElmer, Boston, MA) for 90 min, washed, lysed, immunoprecipitated and separated by SDS-PAGE, with autoradiography as described (19,45).

Functional assays

Spleen B cell proliferation was measured by [3H]thymidine incorporation as described (46). Eight-week-old mice were immunized with 2,4-dinitrophenyl-conjugated keyhole limpet hemocyanin (100 μg, DNP-KLH; Calbiochem-Novabiochem, La Jolla, CA) or were immunized twice with (4-hydroxy-3-nitrophenyl acetyl) conjugated to chicken γ-globulin (50 μg, NP18-CGG) precipitated in alum as described (47). Serum DNP- and NP-specific antibody levels were measured by ELISA as described (46,48), with the relative affinity/avidity of antibody responses assessed as described (48).

Results

Generation of CD20−/− mice

CD20−/− mice were generated through targeted disruption of the Cd20 gene in ES cells by homologous recombination. A targeting vector replaced exons encoding part of the second extracellular loop, the fourth transmembrane domain and the large C-terminal cytoplasmic domain of CD20 with a neomycin resistance gene (Fig. 1A–D). Appropriate gene targeting in ES cells was verified by Southern analysis of DNA digested with EcoRI, BamHI, KpnI and Ssrl. Mice homozygous for Cd20 gene disruption were obtained at the expected Mendelian frequency by crossing heterozygous offspring of founder mice generated using targeted ES cells. Southern blot and PCR analysis of genomic DNA from homozygous offspring further verified appropriate Cd20 gene targeting and the genomic deletion of exons 6–8 (Fig. 1E and F). Wild-type CD20 mRNA was absent in CD20−/− mice as confirmed by PCR amplification of cDNA generated from splenocytes of CD20−/− mice (Fig. 1G). As predicted, a fused CD20-Neor gene transcript was detected at low levels in CD20−/− mice by PCR, which translated into an aberrant CD20 peptide truncated at amino acid 157 that was fused with an 88-amino-acid peptide encoded by the Neo' gene promoter sequence. Absence of cell-surface CD20 protein expression in CD20−/− mice was verified using a panel of 12 mouse anti-mouse CD20 mAb that were reactive with 300.19 and CHO cells transfected with CD20-GFP cDNA, but not with untransfected cells (Fig. 1H).

These mAb reacted with cell-surface CD20 epitopes expressed by CD19+ splenocytes from wild-type mice, but not from CD20−/− mice (Fig. 1I). Therefore, the targeted Cd20 gene mutation abrogated cell-surface CD20 expression.
**B cell development in CD20⁻/⁻ mice**

In the 9 years since their production, CD20⁻/⁻ mice have thrived and reproduced as well as their wild-type littermates and do not present any obvious anatomical or morphological abnormalities, or susceptibility to infections during their first year of life. CD20⁻/⁻ mice had normal frequencies of IgM⁺ B220<sup>lo</sup> pro/pre-B cells, IgM⁺ B220<sup>hi</sup> immature B cells and IgM⁺ B220<sup>hi</sup> mature B cells (Fig. 1J and Table 1), and normal numbers of AA4.1<sup>+</sup> or HSA<sup>hi</sup> B220<sup>lo</sup> immature/transitional B cells in their bone marrow (data not shown). Numbers of blood, spleen and lymph node IgM⁺ B220<sup>lo</sup> B cells were not significantly different between CD20⁻/⁻ mice and their wild-type littermates (Table 1).

B cell IgM expression was significantly lower in CD20⁻/⁻ mice relative to immature and mature B cells of wild-type littermates (Table 1 and Fig. 1J). In addition, there was an ~50% reduction in numbers of IgM<sup>hi</sup> B220<sup>lo</sup> B cells in the spleens of CD20⁻/⁻ littermates. Decreased numbers of IgM<sup>lo</sup> B220<sup>lo</sup> B cells may reflect reduced IgM expression by most B cells, but was not attributable to a loss in spleen marginal zone B cells since the number of cells with a CD1d<sup>hi</sup> CD21⁺ phenotype was not significantly different between CD20⁻/⁻ and wild-type littermates (Table 1). Likewise, numbers of transitional T1 (CD21<sup>lo</sup> HSA<sup>lo</sup>) and T2 (CD21<sup>hi</sup> HSA<sup>hi</sup>) B cells, which represent recent emigrants from the bone marrow, were not reduced (Table 1). Rather, the frequency and number of T1 cells was usually higher in CD20⁻/⁻ mice, similar to the increase in frequency of mature IgM⁺ B220<sup>lo</sup> B cells observed in bone marrow of CD20⁻/⁻ mice. Decreased numbers of IgM⁺ B220<sup>lo</sup> B cells may be attributable in part to a reduction in spleen B1 cells since there was a 64% decrease in the number of CD5⁺ B220<sup>lo</sup> B1a cells within the peritoneal cavity of CD20⁻/⁻ mice. The overall number of IgM⁺ B220<sup>+</sup> B cells in the peritoneum of CD20⁻/⁻ and wild-type littermates was similar due to an increase in the number of CD5⁺ B220<sup>lo</sup> B cells (Table 1 and Fig. 1J). The number of B1b B cells (CD11b⁺ CD5⁻ B220<sup>lo</sup>) was similar in CD20⁻/⁻ and wild-type littermates (Table 1). There were no obvious differences in the size (light scatter properties) of CD20⁻/⁻ B cells isolated from bone marrow, blood, lymph nodes or spleen when compared with B cells from wild-type littermates (not shown). An immunohistochemical analysis of spleen tissue sections revealed an otherwise normal architecture and organization of B220⁺ B cells (data not shown). Therefore, with the exception of decreased IgM expression, a reduction in the IgM⁺ B220<sup>lo</sup> B cell subset in the spleen, and low numbers of B1 cells within the peritoneal cavity, CD20 expression was not an obligate requirement for B cell development and tissue localization.

**CD20⁻/⁺ B cell function**

The proliferative response of purified CD20⁻/⁺ B cells to surface IgM ligation was comparable to wild-type B cells over a range of antibody concentrations (1–40 µg/ml; Fig. 1K and data not shown). Proliferation was also normal when the B cells were activated by LPS (Fig. 1K) over a range of concentrations (0.1–10 µg/ml, not shown) or using IL-4 (10–100 U/ml) plus anti-IgM antibody at a suboptimal (5 µg/ml) concentration. Thus, CD20 loss had no detectable effect on mitogen-induced proliferation. Normal levels of all Ig isotypes were found in sera from CD20⁻/⁻ mice (Fig. 1L). CD20⁻/⁻ mice also generated primary and secondary antibody responses of all isotypes that were similar to those observed in wild-type littermates following immunization with a T cell-dependent antigen, DNP-KLH (Fig. 1M). In addition, CD20⁻/⁻ mice and their wild-type littermates generated equivalent primary and secondary IgM and IgG1 anti-NP antibody responses following immunization with NP-PPV (five mice for each group; not shown). Moreover, the affinities of primary and secondary IgG1 anti-NP antibody responses generated in CD20⁻/⁻ mice were similar to those generated in their wild-type littermates. Therefore, CD20 function was not required for T–B cell interactions, isotype switching or affinity maturation during the generation of humoral immune responses.

**CD20 expression during B cell development**

Using the panel of mouse anti-mouse mAb, two mouse pre-B cell lines (300.19 and 38B9) and two T cell lines (BW5147 and BL4) failed to express CD20 cell surface protein, while the 70Z pre-B line, A2O and AJ9 mature B cell lines, and NS-1 plasmacytoma line were CD20⁺ (Figs 1H and 2A, data not shown). Similarly, CD20 was only expressed by subsets of B220⁺ cells in the bone marrow (Fig. 2B); 30 ± 3% of B220⁺ lymphocytes were CD20⁺, while all B220⁺ B cells were CD20⁺ (n = 6 mice). A similar fraction of CD19⁺ B cells in the bone marrow were CD20⁺ (51 ± 2%, n = 6). Consistent with this, CD43⁺ B220⁺ pro-B cells did not express CD20, while 10 ± 1% (n = 3) of CD43⁺ IgM⁺ B220⁺ pre-B cells expressed CD20 at low densities (Fig. 2G). All CD20⁺ pre-B cells (CD43⁺ IgM⁺ B220⁺) were small based on their light scatter properties, suggesting that CD20 expression was primarily initiated at or near the time of heavy chain expression. Consistent with this, the majority of immature IgM⁺ B220⁺ B cells expressed CD20 (76 ± 9%, n = 3; fraction I, Fig. 2G). A subpopulation of immature IgM⁺ B220⁺ (fraction II, Fig. 2G) or CD19⁺ B cells in the bone marrow expressed CD20 at 277 ± 53% (n = 3) higher densities than mature B20⁺ (fraction III, Fig. 2G) or CD19⁺ B cells (Fig. 2B). Thus, CD20 is first expressed during the small pre-B cell to immature B cell transition, with CD20 expression increasing with maturation and then decreasing with entry into the mature B220⁺ pool of recirculating B cells.

In the spleen, blood, peripheral lymph nodes and peritoneal cavity, the vast majority of IgM⁺ B220⁺ B cells expressed CD20 (Fig. 2C–F). A small subpopulation of CD20⁺ B220⁺ cells was observed among blood (9 ± 1%, n = 3) and spleen (7 ± 2%, n = 3) B cells (Fig. 2C and E). The CD20⁺ B220⁺ B cells in the spleen were predominantly transitional T1 and T2 B cells (Fig. 2H), and are likely to represent recent emigrants from the bone marrow. T1 cells (CD21⁺ HSA⁺) expressed CD20 at 139 ± 23% (n = 3) higher densities than mature B cells, while T2 cells (CD21⁺ HSA⁺) expressed CD20 at 58 ± 11% (n = 3) higher densities. T1 cells (CD21⁺ CD23⁻ IgM⁺) and marginal zone B cells (CD21⁺ CD23⁺ IgM⁺), as described previously (49), also expressed CD20 at levels higher than the majority of spleen B cells (Fig. 2I). Small numbers of CD20⁺ peripheral B cells were observed in some mice, but this number was typically <2% of B220⁺ cells. In the peritoneal cavity, CD20 was expressed similarly by both CD5⁺ and CD5⁻ B cells (Fig. 2F). CD20 was not expressed at detectable levels by other subpopulations of leukocytes in any of the tissues.
examined. Thus, mouse CD20 was expressed exclusively by B cells with expression initiated late during small pre-B cell maturation.

Structural characteristics of CD20

Mouse and human CD20 were compared by precipitating these molecules from surface-labeled B cell lines using the MB20-1 mAb reactive with mouse CD20 and the PB4 mAb reactive with a cytoplasmic epitope of human CD20. Mouse CD20 migrated faster than human CD20 under non-reducing conditions, but also migrated as at least two distinct molecular species with \( M_r \) of 33 and 35,000 (Fig. 3A). Under reducing conditions, mouse CD20 migrated as at least two equally represented molecular species with \( M_r \) of 40 and 42,000 (Fig. 3A). Multiple cell-surface molecules co-precipitated with mouse CD20, as occurs with human CD20 (9,16). The PB4 mAb co-precipitates molecules associated with human CD20 better than mAb that react with CD20 extracellular domains (Tedder, unpublished observations). Co-precipitation of CD20-associated molecules in mouse was not due to mAb

Fig. 2. CD20 expression during B cell development. (A) Immunofluorescence staining of mouse lymphoblastoid cell lines using the MB20-7 (thick line) or isotype control (dashed line) mAb. Single-cell suspensions of lymphocytes isolated from (B) bone marrow, (C) blood, (D) peripheral lymph nodes (PLN), (E) spleens and (F) peritoneal cavities of wild-type C57BL/6 mice were examined by two-color immunofluorescence staining with flow cytometry analysis. (G) CD20 expression by bone marrow B cell subpopulations assessed by four-color flow cytometry analysis. Pro-B cells were identified as CD43+ B220lo cells with the forward- and side-scatter properties of lymphocytes. Pre-B cells were IgM+ CD43+ B220lo cells. Immature and mature CD43+ B cells were divided into three fractions (I, II and III) based on relative IgM and B220 densities. Background fluorescence staining was assessed using isotype-matched control mAb as negative controls (C, dotted lines). (H) CD20 expression by T1, T2 or mature (M) spleen B cells as defined by relative HSA and CD21 expression densities. (I) CD20 expression by T1, T2, marginal zone (MZ) and mature (M) spleen B cells defined by CD23 expression, and relative IgM and CD21 densities. All results are representative of those obtained with three or more 2-month-old wild-type mice.
cross-reactivity since the MB20-1 mAb only reacted with mouse CD20 in western blots and CD20 or other proteins were not precipitated from lysates of CD20±/± B cells (Fig. 3B, data not shown). Surprisingly, mouse CD20 was not a dominant phosphoprotein in resting primary mouse B cells, anti-IgM antibody- or LPS-activated B cells, or B cell lines, even after phorbol myristate acetate (PMA) treatment (Fig. 3C), as it is in human B cells (10,50). Furthermore, PMA-induced phosphorylation of CD20 in LPS-blasts or B cell lines did not lead to a significant shift in CD20 protein Mr, from the faster species to the slower species as characterizes human CD20 (10,11). Thus, mouse and human CD20 share many structural features, with some differences.

Reduced [Ca²⁺], responses in CD20±/± B cells

Despite normal B cell development in CD20±/± mice, splenic B220+ B cells from CD20±/± mice generated reduced [Ca²⁺], responses following IgM ligation with optimal (40 μg/ml; Fig. 4A) and suboptimal concentrations (5 μg/ml; data not shown) of anti-IgM antibodies when compared with wild-type B cells. The kinetics of the immediate [Ca²⁺]i response was not shown) of anti-IgM antibodies when compared with wild-type and CD20±/± B cells. Reduced [Ca²⁺], responses following IgM or CD19 ligation by CD20±/± B cells were not likely to result from differences in internal Ca²⁺ stores or extracellular Ca²⁺ concentrations since thapsigargin- and ionomycin-induced [Ca²⁺], responses were slightly higher on average in CD20±/± B cells than in wild-type B cells (Fig. 4C, data not shown). The decrease in [Ca²⁺], responses in CD20±/± B cells is also unlikely to result from differences in genetic backgrounds. CD20±/± mice and their wild-type littermates were generated from 129 strain ES cells, but were backcrossed with C57BL/6 mice for at least seven generations. In control experiments, IgM-induced and CD19-induced [Ca²⁺], responses were similar, if not identical, for C57BL/6, (C57BL/6 × 129)F₁, and 129 B cells (n = 4, data not shown). Therefore, reduced [Ca²⁺], responses in CD20±/± mice were likely to result from the absence of CD20 function, rather than background differences. Since [Ca²⁺], responses observed following CD19 cross-linking were primarily dependent on transmembrane Ca²⁺ flux and CD19-induced [Ca²⁺], responses were significantly perturbed in CD20±/± mice, CD20 function may be particularly important for transmembrane Ca²⁺ transport.

Signal transduction in CD20±/± B cells

The effect of CD20 loss on B cell transmembrane signal transduction was evaluated by assessing total cellular protein tyrosine phosphorylation in purified B cells following IgM ligation. Overall levels of tyrosine phosphorylation were similar in resting splenic B cells from CD20±/± and wild-type littermates, although some variation was observed between wild-type B cells (Fig. 4B). Lower [Ca²⁺], responses did not result from decreased CD19 expression by CD20±/± B cells (Fig. 4D). Chelation of extracellular Ca²⁺ with EGTA mostly eliminated CD19-induced [Ca²⁺], responses in both wild-type and CD20±/± B cells. Reduced [Ca²⁺], responses following IgM or CD19 ligation by CD20±/± B cells were not likely to result from differences in internal Ca²⁺ stores or extracellular Ca²⁺ concentrations since thapsigargin- and ionomycin-induced [Ca²⁺], responses were slightly higher on average in CD20±/± B cells than in wild-type B cells (Fig. 4C, data not shown). The decrease in [Ca²⁺], responses in CD20±/± B cells is also unlikely to result from differences in genetic backgrounds. CD20±/± mice and their wild-type littermates were generated from 129 strain ES cells, but were backcrossed with C57BL/6 mice for at least seven generations. In control experiments, IgM-induced and CD19-induced [Ca²⁺], responses were similar, if not identical, for C57BL/6, (C57BL/6 × 129)F₁, and 129 B cells (n = 4, data not shown). Therefore, reduced [Ca²⁺], responses in CD20±/± mice were likely to result from the absence of CD20 function, rather than background differences. Since [Ca²⁺], responses observed following CD19 cross-linking were primarily dependent on transmembrane Ca²⁺ flux and CD19-induced [Ca²⁺], responses were significantly perturbed in CD20±/± mice, CD20 function may be particularly important for transmembrane Ca²⁺ transport.

**Fig. 3.** Biochemical characterization of mouse CD20 and CD20±/± B cells. (A) CD20 immunoprecipitated (arrows) from surface-biotinylated Raji (human) and A20 (mouse) B cell lines using the PB4 (human CD20) and MB20-1 (mouse CD20) mAb respectively. Immunoprecipitations with isotype-matched control mAb (C Ab) are shown. The dashed vertical line in the reduced gel panel indicates that the results came from separate gels run in parallel. (B) Western blot analysis of CD20 expression. Lysates of Raji (1 × 10⁶ cells/lane), A20 and the 300.19 B cell lines or purified mouse splenic B cells (5 × 10⁶ cells/lane) were boiled under reducing conditions, separated by SDS-PAGE and transferred to nitrocellulose before probing with the MB20-1 mAb. (C) CD20 phosphorylation in primary B cells and B cell lines incubated with and without PMA. A20 cells (2 × 10⁶), LPS-activated mouse splenic B cells (2 × 10⁶) and Raji cells (1 × 10⁶) cultured in phosphate-free media were incubated in media containing 32PO₄ for 90 min. Half of each culture was incubated with PMA (200 ng/ml) for 30 min before detergent lysis of the cells.
Represents staining of wild-type splenocytes with a control mAb. anti-CD19 mAb with flow cytometry analysis. The dashed line by immunofluorescence staining using phycoerythrin-conjugated similar in B cells from CD20−/− and wild-type littermates. Protein tyrosine phosphorylation after IgM ligation was also B cells from individual mice in individual experiments (Fig. 5A). Altered Ca²⁺ responses in CD20±/± mice. Ca²⁺ responses induced by (A) IgM, (B) CD19 ligation or (C) thapsigargin in Indo-1-loaded B cells from CD20−/− and wild-type littermates. At 1 min (arrow), optimal concentrations of goat anti-IgM F(ab')₂ antibody fragments, anti-CD19 mAb or thapsigargin were added, with or without EGTA present. Increased ratios of Indo-1 fluorescence indicate increased [Ca²⁺]. Results are representative of those from at least six experiments. (D) CD19 expression by splenocytes from CD20−/− (thin line) and wild-type (thick line) littermates was assessed by immunofluorescence staining using phycoerythrin-conjugated anti-CD19 mAb with flow cytometry analysis. The dashed line represents staining of wild-type splenocytes with a control mAb.

B cells from individual mice in individual experiments (Fig. 5A). Protein tyrosine phosphorylation after IgM ligation was also similar in B cells from CD20−/− and wild-type littermates. Phosphorylation of individual signaling molecules downstream of IgM, including Lyn and other Src kinases, phospholipase Cγ, CD19, BTK, and MAP kinase, was also similar in B cells from CD20−/− and wild-type littermates (Fig. 5B). Thus, CD20-deficiency was unlikely to significantly alter basal or IgM-induced transmembrane signaling.

Discussion

The current study demonstrates that the vast majority of mature B cells in mice expressed cell-surface CD20 at significant levels (Fig. 2). This first time characterization of cell-surface CD20 expression in mice was made possible by generating a panel of anti-mouse CD20 mAb. The current studies confirm that mouse cell-surface CD20 expression parallels Cd20 gene transcription (5) and human CD20 expression (2–4). CD20 was expressed after CD19 expression and was predominantly expressed at about the same time as IgM during pre-B to immature B cell development in the bone marrow (Fig. 2G). Most interesting was that CD20 expression increased with maturation and there were B cell subset-specific differences in CD20 expression density. Specifically, a subset of IgMhi B cells that correspond to immature/transitional B cells (51) expressed significantly higher densities of CD20 than their less mature precursors and the mature recirculating B cells found in bone marrow (Fig. 2G). The transitional nature of these B cells was verified by the finding that T1 transitional cells found in the spleen also expressed CD20 at the highest densities, with their progeny T2 transitional cells expressing lower levels of CD20 (Fig. 2H). T1 B cells are recent immigrants from the bone marrow, which develop into T2 B cells that are found exclusively in the primary follicles of the spleen (49). Thus, human and mouse CD20 expression patterns are similar with the exception that high CD20 expression serves as an additional marker for characterizing mouse transitional B cells.

Based on the broad pattern of CD20 expression in mouse, CD20-deficiency would primarily be expected to influence immature and mature B cell function. Rather, B cell development (Fig. 1) was predominantly normal in CD20−/± mice, in agreement with results obtained from an independent line of CD20−/− mice (28). Nonetheless, CD20−/− mice did demonstrate some unique phenotypic and functional characteristics. Most notable was a significant reduction in transmembrane Ca²⁺ influx following CD19 or IgM ligation (Fig. 4). In addition, there was a significant reduction in cell-surface IgM expression in CD20−/± mice relative to their wild-type littermates (Table 1 and Fig. 1). Lower IgM expression was a characteristic feature in our CD20−/± mice, even as they were backcrossed with C57BL/6 mice for seven generations. Lower IgM expression was not noted in the studies of O’Keefe et al. (28), and this is not a characteristic of 129 B cells relative to C57BL/6 B cells. Like the CD20−/± mice of O’Keefe et al., a reduction in peritoneal B1 cell development was found in our CD20−/± mice relative to their wild-type littermates (Table 1 and Fig. 2). As demonstrated by O’Keefe et al. (28), this deficiency may result from a polymorphic difference between the 129 and C57BL/6 strains of mice that is linked to the Cd20 locus since CD20−/− and 129 strain mice had similar low frequencies of B1 cells (data not shown). Despite these differences, the activation of signaling molecules downstream of IgM was similar in CD20−/± mice relative to their wild-type littermates (Fig. 5). Thus, disrupted CD20 expression had selective effects on B cell development and signal transduction.

Human CD20 plays an important role in transmembrane Ca²⁺ influx (13,25–27). Consistent with this, splenic B cells from CD20−/− mice generated significantly reduced [Ca²⁺]i responses following surface IgM or CD19 ligation when compared with B cells from wild-type littermates (Fig. 4). The chelation of extracellular Ca²⁺ attenuated IgM-induced [Ca²⁺]i responses to a more significant extent, but did not eliminate [Ca²⁺]i responses. By contrast, CD19-induced [Ca²⁺]i responses were more dramatically inhibited by CD20 deficiency. The almost complete abrogation of CD19-induced [Ca²⁺]i responses in the presence of EGTA suggests that CD19-induced [Ca²⁺]i responses were primarily dependent on transmembrane Ca²⁺ influx (Fig. 4). Since CD19-induced [Ca²⁺]i responses were most dramatically affected by CD20 loss or the chelation of extracellular Ca²⁺, CD20 expression may predominantly contribute to conductive Ca²⁺ responses. Consistent with this, human CD20 functions either as a component of a cell-surface Ca²⁺ channel or as a direct
expression, there are protein sequence differences that were
human CD20 cDNA-transfected cell lines (13,25±27).

system that complements the previous results obtained using
mice may have decreased [Ca2+]i responses. The incomplete
responses in CD20 ±/± littermates were significantly less than
regulator of Ca2+ channel activity (1). As with all knockout mice
generated in a 129 genetic background, it remains possible
that decreased [Ca2+]i responses in CD20 ±/± B cells result from
129 versus C57BL/6 strain differences or Cd20-linked 129
strain genes that function differently in a C57BL/6 genetic
background. However, both IgM- and CD19-induced [Ca2+]i,
responses in CD20 ±/± littermates were significantly less than
those observed in 129 and C57BL/6 strain B cells, and this
characteristic was not altered during the course of back-
crossing CD20 ±/± mice with C57BL/6 mice for seven gener-
ations. Although O'Keefe et al. concluded that their line of
CD20 ±/± mice had normal IgM-induced [Ca2+]i responses, the
IgM-induced [Ca2+]i response shown in their study was lower in
CD20 ±/± B cells than wild-type B cells and CD19-induced
responses were not evaluated (28). Thus, both sets of CD20±/±
mouse may have decreased [Ca2+]i responses. The incomplete
blockade of [Ca2+]i responses in CD20 ±/± B cells is likely to
reflect the expectation that B cells express numerous Ca2+-
permeant channels that are structurally and functionally
diverse. In addition, proteins of the CD20 or membrane-
spanning 4A (MS4A) family all share significant amino
sequence similarities in their transmembrane domains
(52,53). Thereby, other MS4A family members may also
contribute to transmembrane Ca2+ transport in addition to
CD20, and mouse B cell lines and lymphoid tissues expressed
transcripts for the majority of the currently identified MS4A
family members (unpublished observations). Thus, these
results confirm a role for CD20 in regulating transmembrane
Ca2+ movement in mouse primary B cells and provide a model
system that complements the previous results obtained using
human CD20 cDNA-transfected cell lines (13,25–27).

While mice and humans share similar patterns of CD20
expression, there are protein sequence differences that were
reflected as differences in mouse CD20 phosphorylation and
migration in SDS gels (Fig. 3). Mouse CD20 contains 18 Ser/
Thr residues within its proposed cytoplasmic regions with
multiple consensus sequences for phosphorylation, while
human CD20 contains 26 Ser/Thr residues (5). Human CD20
is significantly downstream from B cell antigen receptor-
induced tyrosine kinase activation, but becomes heavily
serine and threonine phosphorylated in activated B cells and
cell lines (9–11). In fact, CD20 is hyperphosphorylated in hairy
cell leukemia cells which also have unusually high [Ca2+]i
levels (54). Ubiquitous kinases such as protein kinase C,
casein kinase II and calcium/calmodulin-dependent protein
kinase II are likely to phosphorylate CD20 on different residues
with different functional consequences (9–11,50,55,56). For
example, protein kinase C-mediated phosphorylation of CD20
inactivates CD20-associated Ca2+ current, which may be one
molecular mechanism for regulation of transmembrane Ca2+
conductance in B cells (13). By contrast, mouse CD20 was not
hyperphosphorylated following B cell activation (Fig. 3).
Divergent amino acid sequences may explain this difference.
However, this implies that hyperphosphorylation may only be a
small component of CD20 regulation. Alternatively, human and
mouse B cells may regulate CD20 function differently. CD20
may also be regulated by other cell-surface and cytoplasmic
proteins that associate with it in the membrane (9,10). Most
notable in human B cells are uncharacterized cell-surface proteins
of 28–30,000 and 180–200,000 Mr, and 50–60,000 Mr,
cytoplasmic proteins (9,57) that include serine kinases, Src
family tyrosine kinases (p56lck, p59fyn and p59cbl) and 75/
80-kDa tyrosine phosphorylated proteins (16,58). Similar sized
proteins co-purified with mouse CD20 (Fig. 3A). Thus,
mouse CD20 is likely to form oligomeric cell-surface receptor
complexes that may include MS4A family members (13).

Fig. 5. Protein tyrosine phosphorylation in purified splenic B cells of CD20±/± and wild-type littermates. (A) B cells (2 × 107/sample) were
incubated with F(ab')2 anti-IgM antibody fragments for the times shown and detergent lysed. Proteins were resolved by SDS-PAGE,
transferred to nitrocellulose and immunoblotted with anti-phosphotyrosine (anti-pTyr) antibody. The blot was stripped and reprobed with anti-
SHP-1 antibody as a control for equivalent protein loading. The migration of mol. wt markers (kDa) is shown for each panel. (B) Tyrosine
phosphorylation of signaling molecules by CD20±/± B cells. Purified splenic B cells from wild-type and CD20 ±/± littermates were stimulated with
F(ab')2 anti-mouse IgM antibody (40 μg/ml) for the indicated times. Detergent lysates of cells were utilized for western blot analysis with anti-
phosphotyrosine antibodies to assess protein phosphorylation. The blots were subsequently stripped and reprobed with anti-ERK2 antibody to
confirm equivalent protein loading between samples. All results represent those obtained in at least three separate experiments.
The current demonstration that CD20 deficiency does not impart a significant functional disadvantage to B cells explains in part the evolution of CD20-deficient lymphomas following anti-CD20 immunotherapy in humans (59). With the availability of the new reagents described in this study, future experiments will be carried out to address this important, yet complex issue. Nonetheless, the current demonstration that mouse and human CD20 have similar functions and patterns of expression provides a basis for future mechanistic studies that will identify the molecular and cellular mechanisms for tumor regression, and the development of tumor resistance to anti-CD20 mAb treatment.

Acknowledgments

We thank Dr Beverley Kohler, Dr David Ord and Mr Paul Jansen for assistance in the generation and characterization of CD20−/− mice. This work was supported by NIH grants CA81776 and CA54464 and a Basic Science Grant from the Arthritis Foundation.

Abbreviations

- [Ca²⁺]: intracellular calcium
- CGG: chicken γ-globulin
- DNP: 2,4-dinitrophenyl
- ES: embryonic stem
- GFP: green fluorescent protein
- KLH: keyhole limpet hemocyanin
- LPS: lipopolysaccharide
- MS4A: membrane-spanning 4A
- Neot: neomycin resistance
- NP: 4-hydroxy-3-nitrophenyl acetyl
- PMA: phorbol myristate acetate
cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. 


Semin. Oncol. 26:43.


Drugs 58:79.


Oncology 12:1763.


Blood 83:435.


41 Keaney, J. F., Radruch, A., Liegengang, B. and Rajewsky, K. 1979. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. 


Immunity 11:191.


45 Leveille, C., Al-Daccak, R. and Mourad, W. 1999. CD20 is phosphorylated and functionally important for MHC class II and CD40 on human B cell lines. 


Immunity 3:39.


J. Exp. Med. 190:75.


Gonomics 72:119.


Immunogenetics 53:357.


J. Biol. Chem. 264:11282.


Hybridoma 2:17.


Evidence against involvement of the cytoplasmic regions of CD20. 

J. Biol. Chem. 270:22632.


Leuk. Lymph. 43:2335.